Fundraising setback for Stemline as it puts off IPO
This article was originally published in Scrip
New York-based Stemline Therapeutics has decided now is not the right time to go to market, postponing its initial public offering in which it planned to raise up to $42 million by selling 3.5 million shares at $11 to $13 per share (scripintelligence.com, 23 July 2012).
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.